From biologics to biosimilars: Current status and future challenges

A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Bernard M Y Cheung, MA, MB BChir (Cantab), PhD (Cantab), MRCP (UK), FRCP (Edin), FRCP (Lond), FCP, FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, reviews the efficacy and safety of biosimilars, including the concerns and approval process associated with their use.